This document has been archived for historical purposes. (10/23/2018)

Final - October 16, 2018 

MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) 

Centers for Disease Control and Prevention 

1600 Clifton Road, NE, Tom Harkin Global Communications Center, Kent "Oz" Nelson Auditorium 

Atlanta, Georgia 30329 

October 24-25, 2018 

AGENDA ITEM PURPOSE 

Wednesday, October 24 

8:00 Welcome & Introductions 

8:30 Hepatitis A Vaccines 

Introduction 

Background Information 

Homelessness as a risk group: Evidence to Recommendation & Discussion 

Framework and GRADE 

Public comment 

Recommendation vote Vote 

VFC vote VFC Vote 

10:15 B eak

10:30 Pneumococcal Vaccines 

Introduction 

PCV13 Impact on IPD and serotype distribution for the remaining 

disease burden 

Incidence of non-Invasive Pneumococcal Pneumonia before and 

Information after PCV13 recommendation for adults ≥65yo 

& Discussion 

U.S. trends in pneumonia hospitalizations 

Economic analysis of PCV13 for adults ≥65 year old 

Preliminary EtR and GRADE. Summary and timeline 

12:15 Lunch

1:30 Adult Immunization Schedule 

Introduction Information & 

Proposed 2019 adult immunization schedule Discussion 

2:20 Child/Adolescent Immunization Schedule 

Introduction 

Information Proposed 2019 child and adolescent immunization schedule 

& Discussion Public comment 

Vote Immunization schedules recommendations vote 

3:00 B eak

3:15 Japanese Encephalitis 

Introduction 

JE vaccine Evidence to Recommendations Information & JE-VC accelerated schedule recommendation for adults 

Discussion JE-VC pediatric booster and booster dose recommendations 

Conclusions and next steps 

4:15 Anthrax 

Introduction 

NuThrax® 

Information 

Anthrax antitoxin for PEP 

5:00 Vaccine Supply 

5:05 Public Comment 

5:20 Adjourn 

PRESIDER/PRESENTER(s) 

Dr. Amanda Cohn (ACIP Executive Secretary; CDC) 

Dr. Kelly Moore (ACIP, WG Chair) 

Dr. Noele Nelson (CDC/NCHHSTP) 

Dr. Mona Doshani (CDC/NCHHSTP) 

Dr. Noele Nelson (CDC/NCHHSTP) 

Dr. Jeanne Santoli (CDC/NCIRD) 

Dr. Grace Lee (ACIP, WG Chair) 

Dr. Tamara Pilishvili (CDC/NCIRD) 

Mr. Ryan Gierke (CDC/NCIRD) 

Dr. Fernanda Lessa (CDC/NCIRD) 

Dr. Charles Stoecker (Tulane University School of Public 

Health and Tropical Medicine) 

Dr. Almea Matanock (CDC/NCIRD) 

Dr. Paul Hunter (ACIP, WG Chair) 

Dr. David Kim (CDC/NCIRD) 

Dr. Henry Bernstein (ACIP, WG Chair) 

Dr. Candice Robinson (CDC/NCIRD) 

Drs. David Kim and Candice Robinson (CDC/NCIRD) 

Dr. Chip Walter (WG chair) 

Dr. Susan Hills (CDC/NCEZID) 

Dr. Susan Hills (CDC/NCEZID) 

Dr. Susan Hills (CDC/NCEZID) 

Dr. Susan Hills (CDC/NCEZID) 

Dr. David Stephens (ACIP, WG Chair) 

Dr. Paul- Andre de Lame, Mr. Jeff Shearer (Emergent 

BioSolutions) 

Dr. William Bower (CDC/NCEZID) 

page 1 of 2 
This document has been archived for historical purposes. (10/23/2018)

Final - October 16, 2018 

Thursday, October 25 

8:00 Agency Updates & Unfinished Business 

CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO Information Dr. Nancy Messonnier (CDC/NCIRD); Ex Officio Members 

8:30 Human Papillomavirus 

Introduction Dr. Peter Szilagyi (ACIP, WG Chair) 

Vaccine safety update - no association with primary ovarian Ms. Julianne Gee (CDC/NCEZID) 

insufficiency Information & 

Background - Expanded age indication for 9vHPV Dr. Lauri Markowitz (CDC/NCIRD) Discussion 

GRADE Dr. Elissa Meites (CDC/NCIRD) 

Impact and economic analyses Dr. Harrell Chesson (CDC/NCHHSTP) 

Recommendation options Dr. Lauri Markowitz (CDC/NCIRD) 

10:15 B eak

10:45 General Recommendations 

Introduction Dr. Paul Hunter (ACIP, WG Chair) 

Background and posted changes since April 2017 Information & Dr. Andrew Kroger (CDC/NCIRD) 

Vaccine Administration – Vaccinators with conditions that are Discussion 

Dr. Andrew Kroger (CDC/NCIRD) contraindications or precautions 

11:15 Influenza 

Introduction Dr. Chip Walter 

Influenza vaccine effectiveness in preventing influenza-associated Information Dr. Mark Thompson (CDC/NCIRD) hospitalizations during pregnancy & Discussion 

Fluzone Quadrivalent 0.5-mL dose for children aged 6 through 35 Dr. Monica Mercer (Sanofi Pasteur) 

Months 

12:15 Rabies 

Workgroup update Information Dr. Sharon Frey (ACIP, WG Chair) 

12:20 Meningococcal 

Workgroup Update Information Dr. David Stephens (ACIP, WG Chair) 

12:25 Pertussis 

Introduction to Work Group Dr. Henry Bernstein (ACIP, WG Chair) 

Background to current ACIP recommendations (Td and Tdap) and Dr. Fiona Havers (CDC/NCIRD) policy considerations for Tdap revaccination Information 

Adacel revaccination safety and immunogenicity Dr. David Greenberg (Sanofi Pasteur) 

Boostrix revaccination safety and immunogenicity Dr. Leonard Silverstein (GSK) 

1:30 Public Comment 

1:45 Adjourn 

Ac onyms

9vHPV 9-Valent Human Papillomavirus Vaccine 

CDC Centers for Disease Control & Prevention 

CMS Centers for Medicare and Medicaid Services 

DoD Department of Defense 

DVA Department of Veterans Affairs 

FDA Food and Drug Administration 

GRADE Grading of Recommendations Assessment, Development and Evaluation 

HRSA Health Resources and Services Administration 

IHS Indian Health Service 

IPD Invasive pneumococcal disease 

JE-VC Vero cell culture-derived Japanese encephalitis vaccine 

NCHHSTP National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID] 

NCIRD National Center for Immunization & Respiratory Diseases [of CDC/OID] 

NCEZID National Center for Emerging and Zoonotic Diseases [of CDC/OID] 

NVPO National Vaccine Program Office 

PEP Post-exposure prophylaxis 

PCV13 13-valent pneumococcal conjugate vaccine 

Td Tetanus and diphtheria vaccine 

Tdap Tetanus, diphtheria, and pertussis vaccine 

VFC Vaccines for Children 

WG Work Group 

page 2 of 2